(Q38175320)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Androgen receptor signaling in prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Zoran Culig

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

1 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

Cancer and Metastasis Reviews

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

413-427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24384911%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10555-013-9474-0

4 March 2020

exact match

0 references

cites work

Androgen receptors in endocrine-therapy-resistant human prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor levels are upregulated by Akt in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen Stimulates Matrix Metalloproteinase-2 Expression in Human Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen induction of prostate cancer cell invasion is mediated by ezrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor and invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen-induced cell migration: role of androgen receptor/filamin A association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Roles of microRNAs during prostatic tumorigenesis and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen regulation of micro-RNAs in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

miR 488* inhibits androgen receptor expression in prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Targeting continued androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen deprivation increases p300 expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

p300 modulates nuclear morphology in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

BAG-1L protein enhances androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

ART-27, an androgen receptor coactivator regulated in prostate development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Alternatively spliced androgen receptor variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Activation of the human androgen receptor through a protein kinase A signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 regulation of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6: a candidate mediator of human prostate cancer morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-6 regulates androgen synthesis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phosphorylation and activation of androgen receptor by Aurora-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Effect of geldanamycin on androgen receptor function and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0

Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9474-0